Intech Investment Management LLC Invests $90,000 in Aquestive Therapeutics, Inc. (NASDAQ:AQST)

Intech Investment Management LLC purchased a new position in Aquestive Therapeutics, Inc. (NASDAQ:AQST) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 18,032 shares of the company’s stock, valued at approximately $90,000.

Other institutional investors have also recently made changes to their positions in the company. Victory Capital Management Inc. purchased a new stake in shares of Aquestive Therapeutics during the 2nd quarter valued at about $27,000. nVerses Capital LLC purchased a new stake in Aquestive Therapeutics during the third quarter valued at $28,000. The Manufacturers Life Insurance Company purchased a new position in Aquestive Therapeutics in the second quarter worth about $76,000. Financial Advocates Investment Management grew its position in Aquestive Therapeutics by 70.0% during the second quarter. Financial Advocates Investment Management now owns 34,000 shares of the company’s stock valued at $88,000 after buying an additional 14,000 shares during the period. Finally, Harvey Capital Management Inc. purchased a new stake in Aquestive Therapeutics during the third quarter valued at approximately $88,000. Hedge funds and other institutional investors own 32.45% of the company’s stock.

Aquestive Therapeutics Stock Down 3.5 %

Aquestive Therapeutics stock opened at $4.17 on Monday. Aquestive Therapeutics, Inc. has a 52-week low of $1.84 and a 52-week high of $6.23. The company has a market cap of $380.21 million, a price-to-earnings ratio of -9.27 and a beta of 2.62. The firm’s fifty day moving average is $4.94 and its 200 day moving average is $4.03.

Aquestive Therapeutics (NASDAQ:AQST) last released its quarterly earnings results on Monday, November 4th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.01). The company had revenue of $13.54 million during the quarter, compared to the consensus estimate of $12.69 million. During the same quarter in the previous year, the firm earned ($0.03) EPS. On average, equities research analysts anticipate that Aquestive Therapeutics, Inc. will post -0.47 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently weighed in on AQST shares. HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of Aquestive Therapeutics in a research report on Wednesday, November 6th. Leerink Partners boosted their price objective on Aquestive Therapeutics from $12.00 to $13.00 and gave the company an “outperform” rating in a research report on Friday, October 25th. Finally, JMP Securities restated a “market outperform” rating and set a $9.00 target price on shares of Aquestive Therapeutics in a research report on Tuesday, October 8th. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $9.80.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.